Meeting
2014 ASCO Annual Meeting
A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC).
Authors
Cynthia X. Ma
Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
Cynthia X. Ma , Feng Gao , Michael Naughton , Timothy J. Pluard , Steven Sorscher , Allison N Creekmore , Zhanfang Guo , Farrokh Dehdashti , Ben Ho Park , Albert C. Lockhart , L. Austin Doyle , Matthew J. Ellis , Bracha Erlanger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01344031
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 553)
DOI
10.1200/jco.2014.32.15_suppl.553
Abstract #
553
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Evaluation of tumor and circulating cell free (cf) DNA mutations in women with hormone refractory metastatic breast cancer (MBC) enrolled in a phase I study of Z-endoxifen (MC093C).
First Author: Matthew P. Goetz
Poster
2016 ASCO Annual Meeting
Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer.
First Author: Sarika Jain
Poster
2012 ASCO Annual Meeting
A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer.
First Author: Gayathri Nagaraj
Poster
2023 ASCO Annual Meeting
Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer.
First Author: Ezra Rosen